SV

Sanjay Vishnupant Ghawate

Active Director Director DIN 08831445
DIN 08831445 First appointment Aug 2020 Primary industry Chemicals
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Aug 2020
Shareholding value β€’β€’β€’β€’ Premium profile

About Sanjay Vishnupant Ghawate

Data last updated:

Sanjay Vishnupant Ghawate is a Director at Susan Biopharma Private Limited (since 2020). The company operates in Chemicals.

DIN 08831445
Primary Designation Director
Industry Chemicals
First Appointment 12 Aug 2020
Oldest Company Age 6 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Susan Biopharma Private Limited U24290PN2020PTC192897
Director12 Aug 20202020Active

Board colleagues of Sanjay Vishnupant Ghawate

Directorship timeline

Open interactive timeline →
Susan Biopharma Private Limited
Premium access

Shareholding and investment profile for Sanjay Vishnupant Ghawate

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Sanjay Vishnupant Ghawate

Sanjay Vishnupant Ghawate currently holds 1 directorship: Susan Biopharma Private Limited (Director, since 12 Aug 2020).

Sanjay Vishnupant Ghawate was first appointed on 12 Aug 2020 as Director at Susan Biopharma Private Limited.

The current boards of Sanjay Vishnupant Ghawate's companies include Mrugali Sanjay Ghavte (Susan Biopharma Private Limited), Saurabh Sanjay Ghavte (Susan Biopharma Private Limited), Sulbha Sanjay Ghavae (Susan Biopharma Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available